This Market Spotlight report covers the Sarcoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The report estimates that in 2016, there were approximately 403,000 incident cases of sarcoma worldwide, and forecasts that number to increase to 473,700 incident cases by 2025.
- Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (~85%), whilst a smaller proportion were osteosarcomas and other malignant bone tumors (~15%).
- The approved drugs in the sarcoma space focus on targets such as tumor necrosis factor-alpha, microtubules, platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT/c-KIT, and DNA. All the approved drugs are administered via the intravenous route, except for one drug which is available in an oral formulation.
- The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II. Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are being administered via the oral and intravenous routes, with the remainder being subcutaneous, intraocular, subretinal, subconjunctival, intradermal, intratumoral, and topical formulations.
- High-impact upcoming events in the sarcoma space include topline Phase II and Phase III trials results for NY-ESO-1(C259) and TRC105, respectively.
- There were 15 licensing and asset acquisition activities involving sarcoma drugs during 2012-17. The licensing agreement between Adaptimmune and GlaxoSmithKline in 2014 for $1,150m, to develop and commercialize NY-ESO-1(C259), was the largest deal during the period.
- Votrient sales ranked highest in the sarcoma space during 2012-2016 and the sales are forecasted to remain high until 2022. The clinical trials distribution across Phase I-IV indicates that the majority of trials for sarcoma have been in early and midphases of development, with 90.4% of trials in Phase I-II, and only 9.6% in Phase III-IV.
- The US has a substantial lead in the number of sarcoma clinical trials globally, while France leads the major EU markets. Clinical trial activity in the sarcoma space is dominated by completed trials. Merck & Co. has the highest number of completed clinical trials for sarcoma, with 14 completed trials.
- Merck & Co. leads industry sponsors with the highest number of clinical trials for sarcoma, followed by Novartis and Pfizer
Key Topics Covered:
- Key Takeaways
- Disease Background
- Marketed Drugs
- Pipeline Drugs
- Key Upcoming Events
- Key Regulatory Events
- Licensing And Asset Acquisition Deals
- Parent Patents
- Revenue Opportunity
- Clinical Trial Landscape
For more information about this report visit https://www.researchandmarkets.com/research/hb46ch/sarcoma_market?w=4